AstraZeneca Net cash inflow from operating activities by Quarter

AstraZeneca Net cash inflow from operating activities: $2,865M in Q2 2026, down 15.4% from a year earlier.

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 20-F & Form 6-K Consolidated Statement of Cash Flows (Postgres DB).

• Share-based payment charge in operating cash flow ($M)–
• Change in inventories in operating cash flow ($M)–
• Tax paid ($M)-1,525 · Q2 2026
• Net cash outflow from investing activities ($M)–
• Purchase of property, plant and equipment ($M)-763 · Q2 2026
• Disposal of property, plant and equipment ($M)–
• Net cash outflow from financing activities ($M)–
• Issue of loans and borrowings ($M)–
• Repayment of loans and borrowings ($M)–
• Dividends paid ($M)-1 · Q2 2026
• Issue of Ordinary Shares ($M)–
• Purchase of shares by Employee Benefit Trust ($M)–
• Effects of foreign exchange rate changes on cash ($M)–

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.